You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Details for Patent: RE46856

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent RE46856 protect, and when does it expire?

Patent RE46856 protects ALIQOPA and is included in one NDA.

This patent has fifty-one patent family members in forty-two countries.

Summary for Patent: RE46856

Title:	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Abstract:	This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyperproliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
Inventor(s):	Hentemann; Martin (Carlisle, MA), Wood; Jill (Fort Collins, CO), Scott; William (Guilford, CT), Michels; Martin (Koln, DE), Campbell; Ann-Marie (Monroe, CT), Bullion; Ann-Marie (Milford, CT), Rowley; Bruce R. (New Hope, PA), Redman; Aniko (Durham, NC)
Assignee:	Bayer Intellectual Property GMBH (Monheim, DE)
Application Number:	15/398,916
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent RE46856

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Healthcare	ALIQOPA	copanlisib dihydrochloride	POWDER;INTRAVENOUS	209936-001	Sep 14, 2017		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y	Y		TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: RE46856

PCT Information
PCT Filed	December 05, 2007	PCT Application Number:	PCT/US2007/024985
PCT Publication Date:	June 12, 2008	PCT Publication Number:	WO2008/070150

International Family Members for US Patent RE46856

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	064106	⤷ Try a Trial
Australia	2007328008	⤷ Try a Trial
Brazil	PI0720178	⤷ Try a Trial
Canada	2671614	⤷ Try a Trial
Chile	2007003508	⤷ Try a Trial
China	101631464	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.